APRE Aprea Therapeutics, Inc.
$0.51▲ +14.25%
Healthcare
Other
Volume 187.9K
Avg Volume (10D) 187.4K
Key Metrics & Fundamentals
Market Cap
$6.46M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.41 - 1.49
% vs 50 MA
-27.31%
% vs 200 MA
-32.42%
RSI-14
37.6
MACD Histogram
-0.0100
Beta (1Y vs SPY)
0.93
Free Cash Flow
-$3.29M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$4.03M
COGS
–
Operating Exp
$4.03M
Operating Income
-$4.03M
EBIT
-$4.03M
Pretax Income
-$3.59M
Net Income
-$3.59M
EPS (Diluted)
-0.07
Price & Volume History
Loading chart…
Recent News
Aprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision Oncology
GlobeNewswire · Oct 16, 2026 8:30 AM ET
Aprea Therapeutics to Present at October Conferences
GlobeNewswire · Oct 5, 2026 8:30 AM ET
Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium
GlobeNewswire · Sep 22, 2026 8:30 AM ET
Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · Sep 10, 2026 8:00 AM ET
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs
GlobeNewswire · Aug 28, 2026 8:15 AM ET
Aprea Therapeutics Announces Second Quarter 2026 Financial Results
GlobeNewswire · Aug 12, 2026 8:30 AM ET
Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026
GlobeNewswire · Jul 30, 2026 8:00 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See APRE's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.